TSR-033 + dostarlimab + FOLFIRI + bevacizumab

This is a combination therapy consisting of four agents: TSR-033 (a humanized monoclonal IgG4 antibody that targets lymphocyte activation gene-3, LAG-3, acting as an immune checkpoint inhibitor), dostarlimab (an anti-programmed cell death protein 1, PD-1, monoclonal antibody checkpoint inhibitor), FOLFIRI (a chemotherapy regimen containing folinic acid/leucovorin, fluorouracil, and irinotecan, which work together to disrupt cancer cell division and DNA synthesis), and bevacizumab (a monoclonal antibody targeting vascular endothelial growth factor, VEGF, to inhibit angiogenesis). The combination is under clinical investigation, primarily for use in advanced or metastatic microsatellite stable colorectal cancer, aiming to enhance antitumor immune response alongside cytotoxic chemotherapy and anti-angiogenic activity[1][3][5][10].

Other names

GSK4057190AGSK-4057190AGSK 4057190Aanti-LAG-3 monoclonal antibody TSR-033anti-LAG3 monoclonal antibody TSR-033anti-LAG 3 monoclonal antibody TSR-033FOLFIRIbevacizumabJemperli